Nautilus Biotechnology Inc
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprising instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical… Read more
Nautilus Biotechnology Inc (NAUT) - Net Assets
Latest net assets as of September 2025: $169.14 Million USD
Based on the latest financial reports, Nautilus Biotechnology Inc (NAUT) has net assets worth $169.14 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($200.91 Million) and total liabilities ($31.78 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $169.14 Million |
| % of Total Assets | 84.18% |
| Annual Growth Rate | 86.23% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 166.42 |
Nautilus Biotechnology Inc - Net Assets Trend (2018–2024)
This chart illustrates how Nautilus Biotechnology Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Nautilus Biotechnology Inc (2018–2024)
The table below shows the annual net assets of Nautilus Biotechnology Inc from 2018 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $208.73 Million | -21.34% |
| 2023-12-31 | $265.35 Million | -15.74% |
| 2022-12-31 | $314.92 Million | -13.38% |
| 2021-12-31 | $363.58 Million | +1323.30% |
| 2020-12-31 | $-29.72 Million | -264.64% |
| 2019-12-31 | $18.05 Million | +261.04% |
| 2018-12-31 | $5.00 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Nautilus Biotechnology Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 43671.5% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $13.00K | 0.01% |
| Other Comprehensive Income | $57.00K | 0.03% |
| Other Components | $481.68 Million | 230.77% |
| Total Equity | $208.73 Million | 100.00% |
Nautilus Biotechnology Inc Competitors by Market Cap
The table below lists competitors of Nautilus Biotechnology Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Iljin HySolus Co Ltd
KO:271940
|
$121.91 Million |
|
Verusa Holding AS
IS:VERUS
|
$121.92 Million |
|
The Nisshin OilliO GroupLtd.
OTCGREY:NSOMF
|
$121.93 Million |
|
Lucid Diagnostics Inc
NASDAQ:LUCD
|
$121.96 Million |
|
KANGWON Co. Ltd
KQ:114190
|
$121.90 Million |
|
Symphony International Holdings Limited
PINK:SYNNF
|
$121.88 Million |
|
Sintana Energy Inc
OTCQX:SEUSF
|
$121.82 Million |
|
Taiwan Taxi Co Ltd
TWO:2640
|
$121.82 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nautilus Biotechnology Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 265,353,000 to 208,730,000, a change of -56,623,000 (-21.3%).
- Net loss of 70,780,000 reduced equity.
- Share repurchases of 524,000 reduced equity.
- Other comprehensive income increased equity by 312,000.
- Other factors increased equity by 14,369,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-70.78 Million | -33.91% |
| Share Repurchases | $524.00K | -0.25% |
| Other Comprehensive Income | $312.00K | +0.15% |
| Other Changes | $14.37 Million | +6.88% |
| Total Change | $- | -21.34% |
Book Value vs Market Value Analysis
This analysis compares Nautilus Biotechnology Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.59x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 3.81x to 1.59x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $0.70 | $2.65 | x |
| 2019-12-31 | $2.98 | $2.65 | x |
| 2020-12-31 | $-0.90 | $2.65 | x |
| 2021-12-31 | $4.30 | $2.65 | x |
| 2022-12-31 | $2.53 | $2.65 | x |
| 2023-12-31 | $2.12 | $2.65 | x |
| 2024-12-31 | $1.66 | $2.65 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nautilus Biotechnology Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -33.91%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.16x
- Recent ROE (-33.91%) is below the historical average (1769.80%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 12532.00% | 0.00% | 0.00x | 29.16x | $626.10 Million |
| 2019 | -53.28% | 0.00% | 0.00x | 1.03x | $-11.42 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-12.65 Million |
| 2021 | -13.84% | 0.00% | 0.00x | 1.10x | $-86.67 Million |
| 2022 | -18.39% | 0.00% | 0.00x | 1.11x | $-89.42 Million |
| 2023 | -24.00% | 0.00% | 0.00x | 1.15x | $-90.21 Million |
| 2024 | -33.91% | 0.00% | 0.00x | 1.16x | $-91.65 Million |
Industry Comparison
This section compares Nautilus Biotechnology Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nautilus Biotechnology Inc (NAUT) | $169.14 Million | 12532.00% | 0.19x | $121.90 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |